Article Text

other Versions

PDF
Lack of effect of TNFα blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results from two independent prospective studies
  1. Mike J L Peters (mjl.peters{at}vumc.nl)
  1. VU University Medical Center, Netherlands
    1. Pauline H Watt (p.watt{at}clinmed.gla.ac.uk)
    1. University of Glasgow, United Kingdom
      1. Lynne Cherry (l.cherry{at}clinmed.gla.ac.uk)
      1. University of Glasgow, United Kingdom
        1. Paul Welsh (p.welsh{at}clinmed.gla.ac.uk)
        1. University of Glasgow, United Kingdom
          1. Eric Henninger (eric.henninger{at}merckserono.net)
          1. Merck Serono SA, Geneva, Switzerland
            1. Ben A C Dijkmans
            1. VU University Medical Center, Netherlands
              1. Iain B McInnes (i.mcinnes{at}clinmed.gla.ac.uk)
              1. University of Glasgow, United Kingdom
                1. Michael T Nurmohamed
                1. VU University Medical Center, Netherlands
                  1. Naveed Sattar (n.sattar{at}clinmed.gla.ac.uk)
                  1. University of Glasgow, United Kingdom

                    Abstract

                    Background: Adiponectin is an anti-inflammatory and potentially anti-atherogenic molecule. Some recent reports suggest that TNFα blockade therapy increases circulating adiponectin levels but data are sparse and inconsistent.

                    Methods: Data from a double-blind placebo-controlled study of onercept in 126 psoriatic arthritis patients (PsA) and data from pre- and post adalimumab treatment in 171 rheumatoid arthritis (RA) patients were used to examine the effect of TNFα blockade therapy on adiponectin.

                    Results: Despite expected associations of adiponectin to gender and baseline HDL-cholesterol and triglyceride, adiponectin levels did not change over time with TNFα blockade therapy in either group. Absolute change in adiponectin levels were -0.23 ±4.6μg/ml in onercept 50mg and onercept 100mg combined group (versus placebo, p=0.60) in PsA patients and 0.28 ±3.23μg/ml (p=0.66 versus baseline) in RA patients treated with adalimumab.

                    Discussion: These results go against a significant effect of TNFα blockade therapy on circulating adiponectin levels in patients with autoimmune disease.

                    Statistics from Altmetric.com

                    Request permissions

                    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.